FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006155498> ?p ?o ?g. }

• W2006155498 endingPage "381" @default.
• W2006155498 startingPage "372" @default.
• W2006155498 abstract "Background Trypsinogen activation, oxygen radicals, cytokines, leukocyte infiltration, and pancreatic ischemia are important steps in the pathogenesis of necrotizing pancreatitis and associated systemic complications. Several drugs that inhibit those pathogenetic steps attenuated biochemical and histologic changes, while survival remained low. The aim of the present study was to evaluate the benefit of multidrug approaches compared to monotherapies on organ injury and survival in acute experimental pancreatitis in the rat model of retrograde bile injection combined with intravenous cerulein. Methods Necrotizing pancreatitis was induced in rats. After a therapy-free interval of 6 hours, 10 treatment regimens were evaluated: multidrug regimen 1, which contained the protease inhibitor gabexate mesilate, oxygen-free radical scavengers, nitric oxide donor L-arginine, a platelet-activating factor antagonist, and antibodies against intracellular adhesion molecule-1 (ICAM-1) dissolved in dextran, was compared to multidrug regimen 2 (dextran, acetylcysteine, L-arginine, and anti–ICAM-1), monotherapies of each of the drugs, and standard intravascular volume replacement. Results Both multidrug regimens significantly reduced pancreatic and systemic injury and microcirculatory disturbances compared to any of the monotherapies. Treatment with regimen 1 decreased 24-hour mortality to 0% and increased long-term survival to 85% (standard therapy, 70% and 15%, respectively). Multidrug regimen 2 was as effective as regimen 1. Conclusion Treatment of acute necrotizing pancreatitis with multidrug regimens significantly decreases short-term mortality compared to monotherapies. Moreover, multidrug strategies are still effective after a wide therapeutic window. Key to this effective therapy is the inhibition of microcirculatory disturbances and of the systemic inflammatory response. The experimental superiority of the multidrug approach should be confirmed in a clinical trial. Trypsinogen activation, oxygen radicals, cytokines, leukocyte infiltration, and pancreatic ischemia are important steps in the pathogenesis of necrotizing pancreatitis and associated systemic complications. Several drugs that inhibit those pathogenetic steps attenuated biochemical and histologic changes, while survival remained low. The aim of the present study was to evaluate the benefit of multidrug approaches compared to monotherapies on organ injury and survival in acute experimental pancreatitis in the rat model of retrograde bile injection combined with intravenous cerulein. Necrotizing pancreatitis was induced in rats. After a therapy-free interval of 6 hours, 10 treatment regimens were evaluated: multidrug regimen 1, which contained the protease inhibitor gabexate mesilate, oxygen-free radical scavengers, nitric oxide donor L-arginine, a platelet-activating factor antagonist, and antibodies against intracellular adhesion molecule-1 (ICAM-1) dissolved in dextran, was compared to multidrug regimen 2 (dextran, acetylcysteine, L-arginine, and anti–ICAM-1), monotherapies of each of the drugs, and standard intravascular volume replacement. Both multidrug regimens significantly reduced pancreatic and systemic injury and microcirculatory disturbances compared to any of the monotherapies. Treatment with regimen 1 decreased 24-hour mortality to 0% and increased long-term survival to 85% (standard therapy, 70% and 15%, respectively). Multidrug regimen 2 was as effective as regimen 1. Treatment of acute necrotizing pancreatitis with multidrug regimens significantly decreases short-term mortality compared to monotherapies. Moreover, multidrug strategies are still effective after a wide therapeutic window. Key to this effective therapy is the inhibition of microcirculatory disturbances and of the systemic inflammatory response. The experimental superiority of the multidrug approach should be confirmed in a clinical trial." @default.
• W2006155498 created "2016-06-24" @default.
• W2006155498 creator A5000483058 @default.
• W2006155498 creator A5005796927 @default.
• W2006155498 creator A5006706914 @default.
• W2006155498 creator A5028090559 @default.
• W2006155498 creator A5036032282 @default.
• W2006155498 creator A5058360849 @default.
• W2006155498 creator A5067125554 @default.
• W2006155498 creator A5071927479 @default.
• W2006155498 date "2012-03-01" @default.
• W2006155498 modified "2023-10-16" @default.
• W2006155498 title "Multidrug strategies are effective in the treatment of severe experimental pancreatitis" @default.
• W2006155498 cites W1007804022 @default.
• W2006155498 cites W1501811049 @default.
• W2006155498 cites W1502126027 @default.
• W2006155498 cites W1898052913 @default.
• W2006155498 cites W1964980699 @default.
• W2006155498 cites W1966286149 @default.
• W2006155498 cites W1978180398 @default.
• W2006155498 cites W1981708838 @default.
• W2006155498 cites W1982434107 @default.
• W2006155498 cites W1983991013 @default.
• W2006155498 cites W1985045980 @default.
• W2006155498 cites W1988863376 @default.
• W2006155498 cites W1989506871 @default.
• W2006155498 cites W1989800839 @default.
• W2006155498 cites W2013439125 @default.
• W2006155498 cites W2015399419 @default.
• W2006155498 cites W2017809888 @default.
• W2006155498 cites W2018158283 @default.
• W2006155498 cites W2018200471 @default.
• W2006155498 cites W2035527363 @default.
• W2006155498 cites W2046592524 @default.
• W2006155498 cites W2046721360 @default.
• W2006155498 cites W2055869246 @default.
• W2006155498 cites W2060551712 @default.
• W2006155498 cites W2063513460 @default.
• W2006155498 cites W2081903154 @default.
• W2006155498 cites W2094130358 @default.
• W2006155498 cites W2110617812 @default.
• W2006155498 cites W2123617929 @default.
• W2006155498 cites W2131752694 @default.
• W2006155498 cites W2138579645 @default.
• W2006155498 cites W2138590470 @default.
• W2006155498 cites W2148658704 @default.
• W2006155498 cites W2149744820 @default.
• W2006155498 cites W2152526201 @default.
• W2006155498 cites W2153076407 @default.
• W2006155498 cites W2158956822 @default.
• W2006155498 cites W2162767933 @default.
• W2006155498 cites W2313326603 @default.
• W2006155498 cites W2316926039 @default.
• W2006155498 cites W2416441777 @default.
• W2006155498 cites W349989691 @default.
• W2006155498 cites W4247351659 @default.
• W2006155498 cites W4253520066 @default.
• W2006155498 doi "https://doi.org/10.1016/j.surg.2011.07.041" @default.
• W2006155498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21982067" @default.
• W2006155498 hasPublicationYear "2012" @default.
• W2006155498 type Work @default.
• W2006155498 sameAs 2006155498 @default.
• W2006155498 citedByCount "19" @default.
• W2006155498 countsByYear W20061554982012 @default.
• W2006155498 countsByYear W20061554982013 @default.
• W2006155498 countsByYear W20061554982014 @default.
• W2006155498 countsByYear W20061554982015 @default.
• W2006155498 countsByYear W20061554982016 @default.
• W2006155498 countsByYear W20061554982019 @default.
• W2006155498 countsByYear W20061554982021 @default.
• W2006155498 countsByYear W20061554982022 @default.
• W2006155498 crossrefType "journal-article" @default.
• W2006155498 hasAuthorship W2006155498A5000483058 @default.
• W2006155498 hasAuthorship W2006155498A5005796927 @default.
• W2006155498 hasAuthorship W2006155498A5006706914 @default.
• W2006155498 hasAuthorship W2006155498A5028090559 @default.
• W2006155498 hasAuthorship W2006155498A5036032282 @default.
• W2006155498 hasAuthorship W2006155498A5058360849 @default.
• W2006155498 hasAuthorship W2006155498A5067125554 @default.
• W2006155498 hasAuthorship W2006155498A5071927479 @default.
• W2006155498 hasConcept C126322002 @default.
• W2006155498 hasConcept C2775967933 @default.
• W2006155498 hasConcept C2776670229 @default.
• W2006155498 hasConcept C2776999253 @default.
• W2006155498 hasConcept C2781413609 @default.
• W2006155498 hasConcept C71924100 @default.
• W2006155498 hasConcept C90924648 @default.
• W2006155498 hasConcept C98274493 @default.
• W2006155498 hasConceptScore W2006155498C126322002 @default.
• W2006155498 hasConceptScore W2006155498C2775967933 @default.
• W2006155498 hasConceptScore W2006155498C2776670229 @default.
• W2006155498 hasConceptScore W2006155498C2776999253 @default.
• W2006155498 hasConceptScore W2006155498C2781413609 @default.
• W2006155498 hasConceptScore W2006155498C71924100 @default.
• W2006155498 hasConceptScore W2006155498C90924648 @default.
• W2006155498 hasConceptScore W2006155498C98274493 @default.
• W2006155498 hasIssue "3" @default.
• W2006155498 hasLocation W20061554981 @default.

• next